|Bid||2.25 x 0|
|Ask||2.34 x 0|
|Day's Range||2.25 - 2.25|
|52 Week Range||2.21 - 3.56|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
On a per-share basis, the St. Laurent, Quebec-based company said it had a loss of 4 cents. The biopharmaceutical company posted revenue of $88,000 in the period. In the final minutes of trading on Monday, ...
On a per-share basis, the St.-Laurent, Quebec-based company said it had a loss of 5 cents. The biopharmaceutical company posted revenue of $152,000 in the period. The company's shares closed at $3.92. ...
In this article, I’m going to take a look at Nymox Pharmaceutical Corporation’s (NASDAQ:NYMX) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subject amongRead More...
Leading Nymox Pharmaceutical Corporation (NASDAQ:NYMX) as the CEO, Paul Averback took the company to a valuation of US$236.27M. Recognizing whether CEO incentives are aligned with shareholders is a crucial partRead More...
For Nymox Pharmaceutical Corporation’s (NASDAQ:NYMX) shareholders, and also potential investors in the stock, understanding how the stock’s risk and return characteristics can impact your portfolio is important. NYMX is exposedRead More...
Today I will take a look at Nymox Pharmaceutical Corporation’s (NASDAQ:NYMX) most recent earnings update (30 September 2017) and compare these latest figures against its performance over the past fewRead More...